Skip to main navigation
Skip to search
Skip to main content
Sort by
Medicine and Dentistry
Acute Myeloid Leukemia
92%
Overall Survival
48%
Myelodysplastic Syndrome
24%
Hematopoietic Stem Cell
24%
Decitabine
23%
Autologous Stem Cell Transplantation
23%
Lenalidomide
21%
Cell Transplantation
20%
Diffuse Large B-Cell Lymphoma
17%
Neoplasm
17%
Hematopoiesis
17%
Hazard Ratio
16%
Cohort Analysis
15%
Rituximab
14%
Myelodysplastic Syndrome
14%
Azacitidine
14%
T Cell
13%
Acute Myelogenous Leukemia
12%
Cancer Cell
12%
Arm
12%
Leukemia
10%
Progression Free Survival
10%
Peripheral T-Cell Lymphoma
10%
In Vitro
10%
Phagocytosis
9%
Quality of Life
9%
Angioimmunoblastic T-Cell Lymphoma
9%
Positron Emission Tomography-Computed Tomography
8%
Platelet
8%
Population
8%
Chimeric Antigen Receptor T-Cell Immunotherapy
8%
Posttransplant Lymphoproliferative Disease
8%
Disease
8%
Leukemia Cell
7%
Gene Expression Profiling
7%
Positron Emission Tomography
7%
Anemia
7%
Malignant Neoplasm
7%
Anaplastic Large Cell Lymphoma
7%
Mitochondrial Respiration
7%
Hematopoietic Stem Cell
7%
Cancer Registry
6%
Programmed Cell Death
6%
Induction Chemotherapy
6%
Diseases
6%
Core Binding Factor
6%
Multiple Myeloma
6%
Scoring System
6%
Myeloid Malignancy
5%
Clinical Trial
5%
Immunology and Microbiology
Myeloid
100%
B Cell
30%
Overall Survival
29%
Hematopoietic Cell
28%
T Cell
25%
CD47
21%
Cell Transplantation
19%
Hematopoiesis
17%
CD34
17%
Autologous Stem Cell Transplantation
16%
Rituximab
15%
Phagocytosis
15%
Cancer Cell
15%
Macrophage
13%
Arm
12%
Population
11%
Chimeric Antigen Receptor T-Cell
11%
Stem Cell
11%
Graft-Versus-Host Disease
10%
Antineoplastic Activity
9%
Cytotoxicity
8%
Drug Megadose
8%
Gene Expression Profiling
8%
Cyclophosphamide Plus Doxorubicin Plus Prednisolone Plus Rituximab Plus Vincristine
8%
Leukemia Cell
8%
Hematopoietic Stem Cell
8%
Transplant Procedure
7%
Recurrence Free Survival
7%
Lenalidomide
7%
T Cell Receptor
7%
CD20
6%
Mitochondrial Respiration
6%
Acute Graft Versus Host Disease
6%
Positron Emission Tomography
6%
Cytotoxic T-Cell
6%
Tumor Volume
6%
Allogeneic Hematopoietic Stem Cell Transplantation
6%
Tumor Cell
6%
Clonal Evolution
6%
Lymphocyte
6%
Pemphigus vulgaris
5%
Bispecific Antibody
5%
Ecalectin
5%
Isoetarine
5%
Lymphoma Cell
5%
Hematopoietic Stem Cell Transplantation
5%
Leukocyte Count
5%
Keyphrases
Acute Myeloid Leukemia
62%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
26%
Overall Survival
23%
Intensive Chemotherapy
17%
Netherlands
17%
Older Patients
15%
Decitabine
14%
Leukemia Patients
12%
Hazard Ratio
11%
Confidence Interval
10%
Chemotherapy
10%
Improved Outcomes
9%
Leukemia Risk
8%
Clonal Hematopoiesis
8%
Health-related Quality of Life
8%
Large B-cell Lymphoma
8%
Population-based Cohort Study
8%
Azacitidine
8%
Myelodysplastic Syndrome
8%
Chimeric Antigen Receptor T-cell Therapy
8%
Anemia
7%
Lenalidomide
7%
Rituximab
7%
Angioimmunoblastic T-cell Lymphoma
6%
High Risk
6%
Cytopenia
6%
High-risk Myelodysplastic Syndrome
6%
Cytarabine
6%
Progression-free Survival
6%
Chimeric Antigen Receptor T Cells (CAR-T)
6%
Treatment Outcome
6%
High-dose Chemotherapy
5%
Non-myeloablative Transplantation
5%
Nonmyeloablative
5%
Pemphigus Vulgaris
5%
High-risk MDS
5%
Comorbidity
5%
Ara-C
5%
Monocyte Count
5%
Pre-diabetes (pre-DM)
5%
Advanced Glycation End Products
5%
Blood Neutrophils
5%
Neutrophil Count
5%
Skin Autofluorescence
5%
Blood Monocytes
5%
Mitochondrial DNA
5%
Cancer Registry
5%
Induction Chemotherapy
5%
Venetoclax
5%
Acute Myeloid Leukemia Cells
5%
